Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 | ISIN: US75886F1075 | Ticker-Symbol: RGO
Tradegate
24.04.25
17:04 Uhr
524,20 Euro
-2,00
-0,38 %
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
524,40525,4024.04.
524,00528,6024.04.

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
REGENERON PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoSanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD8
MiTruist cuts Regeneron stock price target to $975, maintains Buy4
DiRegeneron to Report Q1 Earnings: What's in Store for the Stock?19
DiRegeneron Expands US Manufacturing With $3 Billion Fujifilm Deal11
DiAmid industry's onshoring push, Regeneron taps Fujifilm Diosynth for $3B, 10-year commercial manufacturing team-up4
DiRegeneron partners with Fujifilm to broaden manufacturing capacity5
DiFujifilm Diosynth Biotechnologies & Regeneron Sign 10-Year U.S. Manufacturing Agreement5
DiCantor Fitzgerald maintains Regeneron stock at Overweight, $695 target3
DiCantor Fitzgerald sets Regeneron stock to Overweight with $695 target2
DiRegeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment202WASHINGTON (dpa-AFX) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth...
► Artikel lesen
DiSanofi/Regeneron's Dupixent granted FDA approval for chronic spontaneous urticaria16
DiRegeneron signs $3 billion deal with contract drugmaker to boost US manufacturing4
DiRegeneron inks $3B deal to boost U.S. manufacturing capacity4
DiRegeneron Pharmaceuticals, Inc.: Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines53New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron's biologic medicines and support high-paying jobs in...
► Artikel lesen
MoSanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria4
MoFDA rejection of extended dosing interval is another piece of bad news for Regeneron's Eylea HD25
MoSanofi and Regeneron's dupilumab approved by FDA for urticaria5
SoBlockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease6
18.04.Regeneron Pharmaceuticals, Inc.: Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application1.426TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter...
► Artikel lesen
18.04.Sanofi, Regeneron win FDA nod for Dupixent in chronic hives8
Seite:  Weiter >>
268 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4